Department of Radiation Oncology, Weill Cornell Medical College, New York, USA.
Sandra and Edward Meyer Cancer Center, New York, USA.
Oncoimmunology. 2021 Feb 19;10(1):1889101. doi: 10.1080/2162402X.2021.1889101.
Radiation therapy (RT) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors mediate poorly overlapping cytostatic and immunostimulatory effects, suggesting that combinatorial regimens may enable supra-additive tumor control. Our preclinical findings demonstrate that administration schedule stands out as a major determinant of efficacy when RT and CDK4/6 inhibitors are combined for breast cancer therapy.
放射治疗（RT）和细胞周期蛋白依赖性激酶 4/6（CDK4/6）抑制剂具有较差的细胞抑制和免疫刺激作用，表明联合方案可能使肿瘤控制具有超相加作用。我们的临床前研究结果表明，当 RT 和 CDK4/6 抑制剂联合用于乳腺癌治疗时，给药方案是影响疗效的主要决定因素。
